<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115900">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01787968</url>
  </required_header>
  <id_info>
    <org_study_id>R01AI083563</org_study_id>
    <nct_id>NCT01787968</nct_id>
  </id_info>
  <brief_title>Congenital Transmission of Lineages I and II of Trypanosoma Cruzi</brief_title>
  <official_title>Congenital Transmission of Lineages I and II of Trypanosoma Cruzi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University School of Public Health and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for Clinical Effectiveness and Health Policy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratory of Parasitology Universite Libre de Bruxelles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inst de Enfermedades Infecciosas y Parasitol Antonio Vidal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lab de Parasitologia Universidad Autonoma de Yucatan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University School of Public Health and Tropical Medicine</source>
  <oversight_info>
    <authority>United States: National Institutes of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      T. cruzi has been divided into two main lineages: T. cruzi I (TcI) and T. cruzi II (TcII,
      including all non-TcI). TcI is predominant in Mexico and Central America, while TcII
      (non-TcI) is predominant in most of South America, including Argentina. In recent studies
      from Argentina, the risk of congenital transmission has been estimated to vary between 2.6
      percent and 7.9 percent. By contrast, we know very little about the congenital transmission
      of TcI. It has been suggested that congenital transmission of T. cruzi is strain related,
      and there is an urgent need to know if TcI transmits differently than TcII (non-TcI). Our
      primary hypothesis is that congenital transmission rates are different for TcI versus TcII.
      Our secondary hypothesis is that the characteristics of T. cruzi infected mothers (e.g.,
      age, parity, transmission in previous pregnancies) and their exposure to vectors are
      different in regions where TcI is predominant versus regions where TcII (non-TcI) is
      predominant. To test these hypotheses, we propose to conduct a prospective study to enroll
      at delivery 13,000 women in Mexico, 7,500 women in Honduras, and 10,000 women in Argentina.
      We will measure transmitted maternal T. cruzi antibodies in cord blood, and, if the results
      are positive, we will identify infants who are congenitally infected by performing
      parasitological examinations on cord blood and at 4-8 weeks, and serological follow-up at 10
      months. We will also perform standard PCR, real-time quantitative PCR, and T. cruzi
      genotyping on maternal blood, standard PCR and T. cruzi genotyping on the cord blood of
      congenitally infected newborns, and serological examinations on siblings. We will estimate
      the exposure to vectors in the household. In addition, we will measure prenatal outcomes
      among infected and uninfected infants with seropositive mothers, and the birth weight of
      their siblings. The specific aims of this study are: 1) To determine the rate of congenital
      transmission of TcI compared to TcII (non-TcI); 2) To compare the T. cruzi infected mothers'
      characteristics and exposure to vectors in regions where TcI is predominant and regions
      where TcII (non-TcI) is predominant; and 3) To describe the birth outcomes of infected and
      uninfected infants born to TcI and TcII seropositive women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Congenital transmission of Trypanosoma cruzi</measure>
    <time_frame>Two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will identify infants who are congenitally infected by performing parasitological examinations on cord blood, on venous blood at 4-8 weeks, and serological follow-up at 10 months. Standard PCR, quantitative real-time PCR (qPCR), and T. cruzi genotyping will be performed on maternal blood and cord blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Birth outcomes</measure>
    <time_frame>Two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Perinatal outcomes (premature rupture of the membranes, birthweight, gestational age, IUGR, and neonatal complications) will be measured among infected and uninfected infants with seropositive mothers, and birthweight will be measured among infected and uninfected siblings.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30500</enrollment>
  <condition>Chagas Disease</condition>
  <arm_group>
    <arm_group_label>TcI, TcII</arm_group_label>
    <description>TcI: T. cruzi seropositive mothers from countries where TcI predominates, or/and with TcI genotyping TcII: T. cruzi seropositive mothers from countries where TcII (non-TcI) predominates, or/and with TcII (non-TcI) genotyping</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, blood with guanidine, dry spots on filter papers
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women delivering in participating hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18 years old or more, informed consent, live birth.

        Exclusion Criteria:

          -  Women residing outside of the follow-up area.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jackeline Alger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inst de Enfermedades Infecciosas y Parasitol Antonio Vidal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Dumonteil, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lab de Parasitologia Universidad Autonoma de Yucatan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Carlier, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratory of Parasitology Universite Libre de Bruxelles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Althabe, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Institute for Clinical Effectiveness and Health Policy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Buekens, MD, PhD</last_name>
    <phone>504-988-5397</phone>
    <email>pbuekens@tulane.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tulane School of Public Health and Tropical Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical Effectiveness and Health Policy</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Althabe, MD, MSc</last_name>
      <email>falthabe@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fernando Althabe, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Belizan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Luisa Cafferata, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio Sosa-Estani, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laboratory of Parasitology, Universite Libre de Bruxelles</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inst. de Enfermedades Infecciosas y Parasitol Antonio Vidal</name>
      <address>
        <city>Tegucigalpa</city>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackeline Alger, MD, PhD</last_name>
      <email>jackelinealger@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Jackeline Alger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lab. de Parasitologia, Universidad Autonoma de Yucatan</name>
      <address>
        <city>Merida</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Dumonteil, PhD</last_name>
      <email>edumonte@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Dumonteil, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rubi Gamboa-Leon, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Honduras</country>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.chagascongenito.info/</url>
  </link>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 7, 2013</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University School of Public Health and Tropical Medicine</investigator_affiliation>
    <investigator_full_name>Dr. Pierre Buekens</investigator_full_name>
    <investigator_title>W.H. Watkins Professor and Dean</investigator_title>
  </responsible_party>
  <keyword>Congenital transmission</keyword>
  <keyword>Trypanosoma cruzi</keyword>
  <keyword>Chagas disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
